Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureMerit E Cudkowicz, Jeremy Shefner, Leonard H van den Berg, Adriano Chio, Dongsheng Fan, Julian Großkreutz, Christian Lunetta, Richard M Tsai, Erik Wallstroem, Li Xiong, Nazem Atassi, Philip Van Damme, Philippe Beauchemin, Annie Dionne, Oliver Blanchard, Angela Genge, Rami Massie, Jeanne Teitelbaum, Grayson Beecher, Peter Dobrowolski, Wendy Johnston, Michael Nicolle, Christen Shoesmith, Marvin Chum, John Turnbull, Agessandro Abrahao, Antonio Saldanha De Castro Perdo, Isaac Hughes, Dhruv Kumar Jain, Denizart Santos Neto, Lorne Zinman, Ji He, Mei Zheng, Hongfu Li, Zhiying Wu, Qianqian Wei, Tianmi Yang, Li Ba, Haishan Jiang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis
10.1038/s41392-023-01713-z · 2023
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
2017
Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications
10.3389/fimmu.2017.01005 · 2017
The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets
10.3389/fnagi.2024.1347987 · 2024
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
10.1038/s41573-020-0071-y · 2020
Single-cell transcriptomic and functional studies identify glial state changes and a role for inflammatory RIPK1 signaling in ALS pathogenesis
10.1016/j.immuni.2025.02.024 · 2025
Identification of RIP1 kinase as a specific cellular target of necrostatins
10.1038/nchembio.83 · 2008
Necroptosis drives motor neuron death in models of both sporadic and familial ALS
10.1016/j.neuron.2014.01.011 · 2014
Activation of necroptosis in multiple sclerosis
10.1016/j.celrep.2015.02.051 · 2015
RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
10.1126/science.aaf6803 · 2016
Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice
10.1179/2045772314y.0000000224 · 2015
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
10.1111/cts.13690 · 2024
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
10.1080/146608200300079536 · 2000
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
10.1016/s0022-510x(99)00210-5 · 1999
An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis
10.1080/14737175.2023.2174018 · 2023
The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials
10.3109/21678421.2012.762930 · 2013
Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis
10.1001/jamaneurol.2017.3339 · 2018
Quantitative strength testing in ALS clinical trials
10.1212/wnl.0000000000002941 · 2016
Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis
10.1016/s0028-3843(14)60153-5 · 2010
Longitudinal biomarkers in amyotrophic lateral sclerosis
10.1002/acn3.51078 · 2020
Clinical significance in the change of decline in ALSFRS-R
10.3109/17482960903093710 · 2010
Unresolved referenced work
2018
Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets
10.3389/fimmu.2022.1059994 · 2022
A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis
10.1073/pnas.2025102118 · 2021
The metabolic intersection between immunosenescence and neuroinflammation in amyotrophic lateral sclerosis
10.1186/s12950-025-00460-y · 2025
Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain
10.1155/2013/480739 · 2013
Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis?
10.3390/ijms20112759 · 2019
Diagnostic delay in amyotrophic lateral sclerosis
10.1111/ene.15874 · 2023
Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the Clarity AD open-label extension study
10.1002/alz.70905 · 2025
A controlled trial of riluzole in amyotrophic lateral sclerosis
10.1056/nejm199403033300901 · 1994
Analysis of start-up, retention, and adherence in ALS clinical trials
10.1212/wnl.0b013e3182a823e0 · 2013
No additional external references are available.